FDA backs away from RFK Jr.’s claims about drug’s promise for autism patients
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
The FDA has backed away from claims made by RFK Jr. regarding a drug's potential benefits for autism patients. However, the FDA's stance on certain treatments and peptides is unclear, with some reports suggesting the agency may be easing restrictions on these substances, while others indicate a continued warning against ineffective autism treatments. The FDA's position and actions on these matters appear to be evolving, with a panel meeting scheduled to discuss broader access to certain peptides.
Full coverage
1
Protect Our Care·Mar 132
BioPharma Dive·Apr 163
NPR·Mar 194
ProPublica·Feb 185
The New York Times·Mar 56
STAT·Apr 157
Politico·Feb 158
PBS·Sep 24